Olympian Clinical Research | Tampa, FL

Research site
4700 North Habana Avenue Suite 303, Tampa, Florida, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


11 of 48
Status: Active
Trial type: Interventional
Funder type: Industry

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Generalized Anxiety Disorder
Drug: Placebo
Drug: SEP-363856

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Moderate to Severe Atopic Dermatitis
Drug: Placebo
Drug: Rezpegaldesleukin

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 2
Drug: Placebo matching Spesolimab Formulation 1

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Trial conditions

Atopic Dermatitis (13 trials)
Dermatitis (13 trials)
Eczema (13 trials)
Psoriasis (10 trials)
Alzheimer Disease (6 trials)
Depression (5 trials)
Depressive Disorder (5 trials)
Major Depressive Disorder (4 trials)
Vitiligo (3 trials)
Compulsive Personality D... (2 trials)

And 14 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems